Objective We sought to evaluate nitric oxide pathway placental gene expression and the epigenome (CpG methylation) among women receiving 17-α hydroxyprogesterone caproate (17-OHPC) with and without recurrent preterm birth (PTB). Study Design This was a case-control study. We prospectively recruited women with ! 1 prior singleton spontaneous PTB <34 weeks receiving 17-OHPC. DNA and RNA were isolated from placentas. RNA abundance (gene expression) and the methylome were analyzed for 84 genes in nitric oxide pathways. Women with recurrent PTB <34 weeks (cases) were compared with those delivering at term (controls). Statistical analysis included multivariable models with Bonferroni's corrected p-values. Results In this study, 17 women met inclusion criteria; 7 preterm cases (delivered at 22.6 AE 2.9 weeks) and 10 term controls (delivered at 38.5 AE 0.8 weeks). Groups had similar PTB history, race/ethnicity, and socioeconomic risk factors for PTB. Twentyseven nitric oxide genes displayed differential expression (p < 0.05 and q < 0.10) when comparing placentas from preterm cases and term controls; all were downregulated in preterm cases. Eight hundred sixty corresponding CpG sites were differentially methylated between the preterm cases and term controls (Bonferroni's p-value <0.05). Conclusion CpG methylation and gene expression patterns in nitric oxide pathway genes differ among placentas from recurrent PTB compared with term birth following 17-OHPC exposure.
Despite a recent modest decrease in the rate of prematurity in the United States from 2006 to 2014, rates of prematurity in the United States rose in 2015, and hundreds of thousands of neonates are delivered too soon every year. A prior spontaneous preterm birth (PTB) is the greatest risk factor for recurrence. 1 Supplementation with 17-α hydroxyprogesterone caproate (17-OHPC) reduces the risk of recurrent PTB by one-third, and offering 17-OHPC to women with a history of a prior spontaneous PTB is the standard of care in the United States. 2 Unfortunately, 17-OHPC is only effective for some women, as 18 to 36% of women experience a recurrent spontaneous PTB despite therapy. The reasons for this variation in response are poorly understood. Pregnancy outcomes among women administered 17-OHPC may be influenced by historical, clinical, pharmacologic, and genetic factors. [3] [4] [5] [6] We and others have recently reported that non-Hispanic black women, as well as those with vaginal bleeding or abruption, a history of abruption in the prior pregnancy, or with a family history of PTB were less likely to respond to 17-OHPC. [3] [4] [5] [6] Caritis et al also demonstrated that those with the lowest 17-OHPC concentrations have the highest likelihood of recurrent spontaneous PTB. 7 Pharmacogenetics studies of prematurity indicate that maternalgenotype may explain some of the variable clinical response to 17-OHPC for recurrent PTB prevention; genes in nitric oxide pathways have been implicated in two separate cohorts.
6,8
Importantly, no data regarding the influence of placental epigenetics are available to predict clinical outcomes among women receiving 17-OHPC. We hypothesized that the placentas of women delivering at term following exposure to 17-OHPC for the prevention of recurrent spontaneous PTB will have detectable changes in nitric oxide pathway gene expression and site-specific CpG methylation (a mediator of gene transcription) during the mid-trimester compared with the placentas of women experiencing a recurrent spontaneous PTB.
Materials and Methods
This was a case-control epigenetic and gene expression association study. Women with a history of one or more singleton nonanomalous spontaneous PTB between 16 and 34 weeks who received 17-OHPC were recruited prospectively at the University of North Carolina at Chapel Hill (Chapel Hill, NC) from 2015 to 2016 into the UNC PTB Biobank. We defined spontaneous PTB as delivery following preterm premature rupture of membranes, cervical insufficiency (defined as asymptomatic cervical dilation or effacement in the second trimester of pregnancy), or idiopathic spontaneous preterm labor (uterine contractions leading to cervical dilation). Pregnancies were dated by a combination of last menstrual period (if available) and ultrasound using standard American College of Obstetricians and Gynecologists criteria.
9 Pregnancy management, including decisions regarding whether to prescribe 17-OHPC and the timing of 17-OHPC administration, was at the discretion of the primary obstetric provider. After delivery, three full-thickness placental biopsies were obtained from the fetal side, 2 cm from the placental cord insertion site using a standard 3 mm punch biopsy tool, placed in Allprotect solution (Qiagen, Valencia, CA), and frozen at À80°C within 24 hours of delivery until analysis. Care was taken to avoid biopsy of placental sites with obvious gross abnormalities. Labor and delivery course, indication for delivery, and neonatal outcomes were collected.
For this study, we selected women with recurrent early PTB <34 weeks' gestation who were enrolled in the UNC PTB Biobank, received 17-OHPC, had placental samples available, and were self-identified as non-Hispanic black, non-Hispanic white, or Hispanic race/ethnicity. The control group was composed of women enrolled in the UNC PTB Biobank who also had a history of a prior PTB and received 17-OHPC but delivered at term (at or beyond 37 weeks' gestation). Controls were selected at random to match the composition of the case group with regard to maternal race/ethnicity and history of cervical insufficiency. We excluded women carrying fetuses later diagnosed with major congenital anomalies or aneuploidy and those with known Mullerian anomalies.
All clinical data were collected using standardized questionnaires, and interviews were performed by trained research assistants. Study data were collected and managed using Research Electronic Data Capture (REDCap) tools, a secure, web-based application designed to support data capture for research studies, hosted at the University of North Carolina at Chapel Hill. 10 The electronic medical record was also reviewed to supplement and verify clinical data provided by participants during interviews. This study was approved by the Institutional Review Board at the University of North Carolina at Chapel Hill, and all women provided written, informed consent prior to participation. DNA and RNA were isolated from placental tissue. Placental biopsies were blotted to remove residual Allprotect reagent and homogenized in Buffer RLT Plus with B-mercaptoethanol (Qiagen). DNA and RNA sequences more than 18 nucleotides in length were extracted from placental tissue using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen) according to manufacturer's instructions. Isolated DNA was then bisulfite converted using the EZ DNA methylation kit (Zymo Research, Irvine, CA). RNA abundance (gene expression) was analyzed using the Human Nitric Oxide Signaling Pathway RT 2 Profiler PCR Array, version 4.0 (SABiosciences, Qiagen) per manufacturer's instructions. CpG methylation was assessed by hybridizing bisulfite converted DNA onto the Illumina MethylationEPIC BeadChip array (Illumina, Inc., San Diego, CA). This platform assesses DNA methylation levels of 850,000 probes at a single nucleotide resolution. Methylation levels were calculated and expressed as β-values: β ¼ intensity of the methylated allele (M)/(intensity of the unmethylated allele [U] þ intensity of the methylated allele [m] þ100). Probes with poor detection (p < 0.01) were removed prior to analysis. Quantile normalization was then performed to ensure comparability across samples. Probes representing single nucleotide polymorphisms were removed as variability at these loci arise from either allelic composition or altered methylation profiles. Finally, methylation data for the 84 genes represented on the nitric oxide pathway RNA expression array (as described earlier), represented by 3,672 probes, were selected for further analysis.
Bivariate analyses were conducted to compare recurrent early PTB cases to term controls using t-test and Fisher's exact test as appropriate using STATA statistical software (version 13.1, College Station, TX). We compared the relative expression of 84 nitric oxide pathway genes between placentas from PTB cases and term controls. Probes corresponding to all genes significant (p < 0.05 and q < 0.10) in the initial gene expression analysis were then evaluated for differences in CpG methylation, in relation to PTB case status using an analysis ofcovariance (ANCOVA) model. We controlled for several covariates, selected a priori due to known association with PTB, including maternal age, race, prepregnancy body mass index, household income, and earliest prior PTB. The ANCOVA analysis was conducted with Partek Genomic Suite 6.4 (St. Louis, MO). CpG sites corresponding with the significant genes on the nitric oxide signaling pathway gene array were evaluated. To determine if CpG methylation was associated with the expression of genes involved in the nitric oxide pathway, Pearson's correlation coefficients, and associated p-values were calculated, comparing the placental methylome between early recurrent PTB cases and term controls. Statistical significance was set at Bonferroni's corrected p-value threshold of 0.05.
Results
A total of 17 women met the inclusion criteria for the study. There were 7 preterm cases (delivered at 23.9 AE 5.1 weeks, range 17.9-33.4 weeks) and 10 term controls (delivered at 38.5 AE 0.8 weeks). The groups were similar with regard to PTB history, race/ethnicity, and socioeconomic risk factors for PTB (►Table 1). All were self-reported nonsmokers during pregnancy. Placentas were processed and frozen at similar times postdelivery for cases and controls (13.0 AE 13.7 hours for cases and 24.0 AE 6.2 hours for controls, p ¼ 0.23).
The expression of 84 genes in the nitric oxide pathway was compared between preterm and term placentas. Twenty-seven nitric oxide genes were differentially expressed (p < 0.05 and q < 0.10) when comparing placentas from preterm cases and term controls; all were downregulated in preterm cases (►Table 2). The five most significant differentially expressed genes in the preterm placentas relative to term placentas were PRDX2 (peroxiredoxin-2; differentially expressed genes overlapped with those found by Winn et al to be associated with gestational age, including PRDX2, EGFR (epidermal growth factor receptor), and GLRX2 (glutaredoxin 2). The 27 differentially expressed genes in the placenta were subsequently analyzed in association with changes in CpG methylation in the placenta. A total of 860 CpG sites corresponding to the 27 genes were found to be differentially methylated between the preterm cases and term controls (Bonferroni's p-value <0.05). A nearly equal proportion of differentially methylated sites were hypomethylated (decreased, 47%) as were hypermethylated (increased, 53%) in progesterone responders compared with progesterone nonresponders. The number of differentially methylated sites in each of these 27 genes is displayed, by gene, in ►Table 3. The mean fold change for progesterone responders versus nonresponders is also shown in ►Table 3. Finally, the leading CpG methylation results (according to the Bonferroni's corrected p-value) for each of the 27 genes are shown in ►Table 4.
Comment
We found differences in the methylation and gene expression patterns in nitric oxide pathway genes in term versus preterm placentas following exposure to 17-OHPC. Gene expression changes in the placenta at delivery are associated with changes in CpG methylation in the placenta at delivery. These data provide further evidence implicating nitric oxide pathways in recurrent PTB among women on 17-OHPC. Since all women received 17-OHPC, we are unable to compare placentas among those with recurrent PTB with and without 17-OHPC exposure. We speculate that the observed differences are not a direct effect from 17-OHPC exposure, but may reflect a certain pattern of methylation and/or gene expression changes in placentas of those destined to respond or not respond to progesterone therapy. However, our methodology does not allow us to directly understand the interaction between 17-OHPC exposure, gene expression, CpG methylation, and birth outcomes. Our finding of differential gene expression within the nitric oxide pathway is biologically plausible. Specifically, progesterone and nitric oxide are tightly linked, beginning at the establishment of pregnancy.
12 Progesterone is known to stimulate nitric oxide synthesis via transcriptional and nontranscriptional pathways in human endothelial cells. [13] [14] [15] [16] Nitric oxide expression generally increases during pregnancy and decreases before parturition, 17 and nitric oxide is known to regulate vasodilation, smooth muscle relaxation, and the inflammatory response during pregnancy. However, myometrial relaxation occurs in a cyclic guanosine monophosphate (cGMP)-independent manner. 18 In other areas of the body (e.g., blood vessels), changes may be activated in a nongenomic manner by estrogen, though there are no specific studies in pregnancy or in the myometrium. 19, 20 The bactericidal, viricidal, and fungicidal activities of macrophages are determined by nitric oxide pathways. 21 Inflammation and infection are established etiologies of PTB, particularly early PTB as examined in the current analysis. Though previously thought to be associated only with iatrogenic PTB (e.g., due to preeclampsia), recent evidence implicates abnormal placentation, including malperfusion, in spontaneous PTB. 22, 23 Finally, nitric oxide influences uterine activity by increasing cGMP, which in turn relaxes uterine myometrium.
24-26
In our previous work evaluating 17-OHPC pharmacogenomics, we found a relationship between maternal nitric oxide synthase 1 genotype and nitric oxide pathway genes and 17-OHPC responder status. However, it is difficult to compare genotype results (DNA) with gene expression results (RNA) and epigenetics (CpG methylation), particularly across subjects (maternal vs. fetal genetics). In one of the few studies of the contribution of fetal gene expression to PTB, Vora et al found higher fetal gene expression of nitric oxide synthase 1 and d-aspartate oxidase in mid-pregnancy amniotic fluid supernatant among pregnancies destined to deliver preterm compared with term. 27 However, in the Vora et al's study, the focus was not on pharmacogenomics and no information is available regarding progesterone supplementation. Further, the NOS3 gene was not one of the 65 genes evaluated on their custom panel.
Many of the evaluated genes also have biologic plausibility for PTB. Space limitations preclude in-depth discussion of all genes of interest. Notably, however, two genes in the peroxiredoxin family of genes (PRDX2 and PRDX5) were downregulated in preterm placentas compared with term placentas. The family of peroxiredoxin genes has previously been implicated in cervical ripening 28, 29 and the presence of PRDX2 is considered crucial to regulation of oxidative stress at the placental level.
30,31
We speculate that loss of this protective mechanism to counteract oxidative stress in preterm mothers and placentas may have contributed to recurrent PTB. However, since Winn et al found gestational age variation in PRDX2, 11 we cannot exclude this as a possible explanation for our result. We also found that expression of SIRT2 was downregulated in preterm placentas. In a study of women with severe, early-onset preeclampsia, Hannan et al reported that SIRT2 localizes to the syncytiotrophoblast, villous leukocytes, and vasculature in preterm placentas, and that those with severe preeclampsia and fetal growth restriction have reduced SIRT2 protein expression. 32 Further, in a study of the relationship between transcriptomic profiles of chorioamniotic membranes of preterm neonates with and without neurologic impairment at the age of 2 years, SEPP1 (selenoprotein P, plasma 1). This study should be interpreted with several limitations in mind. We were limited by the overall small size of the cohort. Despite our sample size, however, the results were significant even when performing Bonferroni's correction for the large number of tests. Nonetheless, these findings should be confirmed in larger studies. Further, it is possible that our findings were confounded by gestational age. However, this confounding was mitigated somewhat by comparing differentially expressed genes to a known database of genes with changes in expression associated with gestational age and finding little overlap. In addition, the majority of women in this cohort had a history of one or more pre-or periviable deliveries. It is uncertain whether these results would therefore apply to a more generalized PTB population with less severe phenotypes. Due to logistic considerations, placentas were processed up to 48 hours postdelivery. Traditionally, immediate processing to stabilize RNA has been considered the gold standard, but recent research has shown that storage at room temperature (4°C) for up to 48 hours prior to dissection and freezing does not alter RNA quality.
33
Finally, it is possible that differences in exposure to progesterone may have impacted our results. However, though some women received both 17-OHPC combined with vaginal progesterone, the exposure to vaginal progesterone is equal in both groups and therefore not expected to alter results. Women who delivered at term most likely received their last 17-OHPC injection 1 to 3 weeks prior to delivery, whereas those who delivered preterm most likely received their last 17-OHPC injection within a week of delivery. The half-life of 17P is $10 days, 34 so even those women who received their last injection at 36 0/7 weeks' gestation would still be expected to have 25% of their circulating 17-OHPC at 39 weeks (two half-lives), and we do not anticipate that gene expression and methylation changes occur that rapidly following subsequent "17P withdraw." Further, as described earlier, we posit that placental methylation and gene expression changes may not be in direct "response" to 17P but that a certain pattern of methylation and gene expression may be associated with response or nonresponse. This study also had several strengths. Our findings provide consistent evidence of a relationship between genetic variation in nitric oxide pathways and recurrent PTB among women exposed to 17-OHPC, a biologically plausible hypothesis. By linking CpG methylation and gene expression in the same samples, we provide a possible mechanism by which genes are turned "on" or "off," given that methylation within promotor regions of genes typically represses gene transcription. Our study is strengthened by the exclusion of women who delivered between 34 and 37 weeks' gestation ("late preterm"), a time period when the etiology for PTB is traditionally very heterogenous, and may include nonspontaneous indications. Our approach, evaluating placental tissue and then examining both gene expression and CpG methylation is integrative, evaluating not only the end result of gene expression changes but the likely biologic changes contributing to them.
In conclusion, we found distinct changes in placental nitric oxide pathway gene expression and CpG methylation in women with recurrent PTB on 17-OHPC. In the future, evaluation of whether these epigenetic changes are also present in the mid-trimester of women at highest risk of PTB may provide the basis for development of diagnostic tests to identify women at risk for recurrent PTB despite 17-OHPC prophylaxis. Future studies might also investigate whether there are changes at the level of the maternal decidua and/or uterus from women delivering by cesarean section. This has the potential to lead to the testing of alternative therapies for women who are likely to deliver preterm despite 17-OHPC. 
